MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...

Benlysta (belimumab) is a prescription drug that’s used to help manage certain types of lupus. It’s not known whether Benlysta is safe to use while pregnant or breastfeeding. If you can become ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...

Benlysta (belimumab) is a biologic developed by Human Genome Sciences in partnership with GlaxoSmithKline (GSK). A biologic is a large, complex molecule that is produced using recombinant DNA ...

Benlysta is an immunosuppressant medication that can lower the amount of antibodies your immune system produces. This makes it effective in managing different forms of lupus. Benlysta works by ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...

Please provide your email address to receive an email when new articles are posted on . Children treated with belimumab were more likely to achieve primary efficacy renal response vs. standard ...

Belimumab autoinjector is now approved and available for pediatric patients with lupus nephritis. The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for ...